From the Podium to Practice: Translating Emerging Transthyretin amyloid cardiomyopathy (ATTR-CM) Evidence Across Underserved and Underrecognized Populations | ACC 2026 Congress Coverage

From the Podium to Practice: Translating Emerging Transthyretin amyloid cardiomyopathy (ATTR-CM) Evidence Across Underserved and Underrecognized Populations | ACC 2026 Congress Coverage is organized by Iridium Continuing Education, Global Education Group.

Release: 05/29/2026
Expiration: 05/29/2027

Program Overview:
Transthyretin amyloid cardiomyopathy (ATTR-CM) remains under-recognized in clinical practice, particularly among women, where differences in phenotype and reliance on traditional diagnostic thresholds contribute to delayed or missed diagnosis. Recent data presented at ACC.26 provide important insights into disease recognition, diagnostic considerations, and emerging therapeutic evidence with direct implications for clinical care.

This activity is designed to translate key findings from ACC.26 into practical, clinically relevant insights that can be applied in real-world settings. Learners will review emerging evidence, examine limitations in current data, and understand how these factors influence recognition, diagnosis, and management of ATTR-CM in women.

The activity emphasizes application of evidence to practice, including identification of sex-specific clinical features, consideration of adjusted diagnostic thresholds, and integration of evolving therapeutic data into clinical decision-making. Interactive elements are incorporated throughout to support engagement and reinforce understanding of key concepts.

Learning Objectives:
Upon completion of this activity, the participant should be able to:

• Interpret recent ATTR-CM clinical trial data and emerging evidence. 
• Identify ATTR-CM features more commonly seen in women.
• Apply adjusted diagnostic thresholds in women presenting with HFpEF and ventricular wall thickening.
• Select appropriate ATTR-CM therapy using emerging evidence, individualized to patient characteristics and disease stage.